Everolimus and Exemestane for Postmenopausal Women with Letrozole or Anastrozole-Resistant Breast Cancers

Everolimus is a drug that targets the mTOR pathway, which is over-activated in many cancers and associated with resistant to hormonal therapy in breast cancers. In this study, everolimus was used in combination with exemestane to treat postmenopausal women with advanced ER+ HER2- breast cancers that had become resistant to letrozole or anastrozole. Treatment with everolimus significantly reduced the risk of cancer progression by 57% versus exemestane alone and increased overall progression free survival from 2.8 mths to 6.9 mths for all subgroups. I like this approach because it targets the PI3K/mTOR pathway (associated with resistance to estrogen therapy) and provides treatment options for patients that have become resistant to hormonal therapies. Most importantly, the benefits of this combination were consistent across all of the clinical trials subgroups including the number of prior therapies, presence of visceral disease, bone metastases and prior use of chemotherapy.
Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer who are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial.

NEW! GENE TARGETED NUTRACEUTICAL DIET FOR ESTROGEN POSITIVE BREAST CANCERS NOW AVAILABLE FOR DOWNLOAD


Speak Your Mind

*